Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group, publicly listed in Japan (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK).
Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected technology and platform.
Our primary focus is the discovery and early development of new medicines originating from our proprietary G Protein-Coupled Receptor (GPCR)-targeted StaR® technology and Structure-Based Drug Design (SBDD) platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.
Our Company has established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.
Sosei Heptares has approximately 161 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.
This position will lead Drug Substance Design and CMC from candidate nomination through to clinical development for all Sosei Heptares portfolio across several therapeutic areas including projects partnered with collaborators. As part of the Preclinical Development Group, this position will ensure integration of drug substance CMC strategy and operations within overall drug development strategy and timelines across all projects. The position will also ensure state-of-the-art drug substance chemistry design at the interface between discovery and development for new candidates. The position will ensure progression of multiple projects in preclinical and clinical development through an extensive network of external vendors and collaborators.
Key responsibilities:
The successful candidate is expected to have:
The successful candidate will be employed by Heptares Therapeutics Ltd, a UK wholly owned subsidiary of Sosei Group Corporation.
We offer a competitive salary and benefits package commensurate with qualifications and experience.
Heptares is an equal opportunities employer.
Applications should include a CV and covering letter, providing a short description of the background to their interest in the role. Please apply through our on-line jobs’ portal with your application in pdf format, quoting reference number 2021-CMC-DS-03. The closing date for applications is 31st December 2021.
Sosei Heptares does not accept speculative or unsolicited CVs from agencies. All speculative or unsolicited CVs submitted without an agreement in place will be considered Sosei Heptares' property and will not obligate us to pay a referral fee.